TrialBreast cancer research : BCR2026

Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer.

N de Gruil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.